GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing King-Friend Biochemical Pharmaceutical Co Ltd (SHSE:603707) » Definitions » Current Deferred Taxes Liabilities

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Current Deferred Taxes Liabilities : ¥0 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nanjing King-Friend Biochemical Pharmaceutical Co Current Deferred Taxes Liabilities?

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Nanjing King-Friend Biochemical Pharmaceutical Co's current deferred tax liabilities for the quarter that ended in Mar. 2024 was ¥0 Mil.

Nanjing King-Friend Biochemical Pharmaceutical Co Current Deferred Taxes Liabilities Historical Data

The historical data trend for Nanjing King-Friend Biochemical Pharmaceutical Co's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing King-Friend Biochemical Pharmaceutical Co Current Deferred Taxes Liabilities Chart

Nanjing King-Friend Biochemical Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nanjing King-Friend Biochemical Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nanjing King-Friend Biochemical Pharmaceutical Co Current Deferred Taxes Liabilities Related Terms

Thank you for viewing the detailed overview of Nanjing King-Friend Biochemical Pharmaceutical Co's Current Deferred Taxes Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Business Description

Traded in Other Exchanges
N/A
Address
1/16 Xuefu Road, Nanjing High-Tech Zone, Nanjing, CHN, 210061
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.
Executives
Huang Xi Wei Director
Liu Zu Qing Supervisors
Xie Ju Hua Director
Wu Gui Ping senior management
Tang Yong Qun Director
Qian Xiao Jie senior management

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Headlines

No Headlines